Mirati Therapeutics Total Revenue

Mirati Therapeutics (MRTX) currently reports a total revenue of $38M as of September 2023. That compares with $12M in the prior-year period — up 223.6% year over year. That is below the Healthcare sector average of $110B. Use the charts on this page to explore Mirati Therapeutics's total revenue history and peer comparisons.

Mirati Therapeutics's total revenue increased from $12M to $38M — a 223.6% year-over-year increase (period ending September 2023). Watching multi-year history on the chart below helps separate one-off swings from a lasting trend.

Mirati Therapeutics's total revenue of $38M is lower than the Healthcare sector average of $110B. That is roughly 100.0% below the sector mean. A reading lower peers can reflect different growth expectations, capital structure, or profitability — so it is worth checking the peer comparison chart before drawing conclusions.

Mirati Therapeutics reported $38M in total revenue as of September 2023. That compares with $12M in the prior-year period — up 223.6% year over year. Absolute dollar amounts are most useful when compared with prior periods, peers, and related line items such as revenue, assets, or liabilities on Stockcircle.

Start with the current total revenue of $38M, then check the historical chart for trend and the peer comparison chart for relative positioning. The Healthcare average is $110B. From there, open related valuation or income-statement pages for Mirati Therapeutics, and consider following MRTX for alerts when major investors trade the stock.